Cholangiocarcinoma-controversies and challenges

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 4, 2011, Pages 189-200

  Patel, Tushar ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOLASTATIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; OXALIPLATIN; PANITUMUMAB; PEMETREXED; SELUMETINIB; SORAFENIB; VANDETANIB;

ADJUVANT THERAPY; BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHEMOEMBOLIZATION; CHOLANGIOGRAPHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DUCTAL CHOLANGIOCARCINOMA; HUMAN; LIVER TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEREOTACTIC BODY RADIATION THERAPY; TUMOR CLASSIFICATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; PHENOTYPE; RISK FACTORS;

EID: 79953705666     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.20     Document Type: Review

References (114)

1. Welzel, T. M. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin. Gastroenterol. Hepatol. 5, 1221-1228 (2007). (Pubitemid 47496233)
2. Shaib, Y. H. et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am. J. Gastroenterol. 102, 1016-1021 (2007). (Pubitemid 46698225)
3. Welzel, T. M., McGlynn, K. A., Hsing, A. W., O'Brien, T. R. & Pfeiffer, R. M. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J. Natl Cancer Inst 98, 873-875 (2006). (Pubitemid 43923444)
4. Patel, T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2, 10 (2002).
5. Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33, 1353-1357 (2001) (Pubitemid 32496970)
6. Patel, T. Cholangiocarcinoma. Nat Clin. Pract. Gastroenterol. Hepatol. 3, 33-42 (2006). (Pubitemid 43102075)
7. DeOliveira, M. L et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245, 755-762 (2007).
8. Nagino, M. et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann. Surg. 243, 364-372 (2006). (Pubitemid 43327769)
9. Hemming, A. W., Reed, A. I., Fujita, S., Foley, D. P. & Howard, R. J. Surgical management of hilar cholangiocarcinoma. Ann. Surg. 241, 693-699 (2005).
10. Rea, D. J., Rosen, C B., Nagorney, D. M., Heimbach, J. K. & Gores, G. J. Transplantation for cholangiocarcinoma: when and for whom? Surg. Oncol. Clin. N. Am. 18, 325-337 (2009).
11. Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273-1281 (2010).
12. Gao, F., Bai, Y., Ma, S. R., Liu, F & Li, Z. S. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J. Hepatobiliary Pancreat Sci. 17, 125-131 (2010).
13. Ortner, M. A. Photodynamic therapy for cholangiocarcinoma: overview and new developments. Curr. Opin. Gastroenterol. 25, 472-476 (2009).
14. Quyn, A. J., Ziyaie, D., Polignano, F M. & Tait, I. S. Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB (Oxford) 11, 570-577 (2009).
15. Ortner, M. E. et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study Gastroenterology 125, 1355-1363 (2003). (Pubitemid 37409755)
16. Jinawath, N. et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology 44, 1025-1038 (2006). (Pubitemid 46489566)
17. Yang, B., House, M. G., Guo, M., Herman, J. G. & Clark, D. P Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod. Pathol. 18, 412-420 (2005). (Pubitemid 40395361)
18. Xu, M. J. et al. Identification and characterization of microRNAs in Clonorchis sinensis of human health significance. BMC Genomics 11, 521 (2010).
19. Kawahigashi, Y et al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cel ines reveals biliary epithelial cell-specific microRNAs. J. Nippon Med. Sch. 76, 188-197 (2009).
20. Meng, F et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129 (2006). (Pubitemid 43816961)
21. Nakeeb, A. et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann. Surg. 224, 463-473 (1996).
22. Sano, T et al. Prognosis of perihilar cholangiocarcinoma: hilar bile duct cancer versus intrahepatic cholangiocarcinoma involving the hepatic hilus. Ann. Surg. Oncol. 15, 590-599 (2008).
23. Ebata, T et al. The concept of perihilar cholangiocarcinoma is valid. Br. J. Surg. 96, 926-934 (2009).
24. Klatskin, G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am. J. Med. 38, 241-256 (1965).
25. Farges, O. & Fuks, D. Clinical presentation and management of intrahepatic cholangiocarcinoma. Gastroenterol. Clin. Biol. 34, 191-199 (2010).
26. Gatto, M. & Alvaro, D. Cholangiocarcinoma: risk factors and clinical presentation. Eur. Rev. Med. Pharmacol. Sci. 14, 363-367 (2010).
27. Khan, S. A., Toledano, M. B. & Taylor-Robinson, S. D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10, 77-82 (2008). (Pubitemid 351934989)
28. Singh, P & Patel, T Advances in the diagnosis, evaluation and management of cholangiocarcinoma. Curr. Opin. Gastroenterol. 22, 294-299 (2006). (Pubitemid 44090067)
29. Shaib, Y H., El-Serag, H. B., Davila, J. A., Morgan, R. & McGlynn, K. A. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 128, 620-626 (2005). (Pubitemid 40585364)
30. Chung, Y E. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29, 683-700 (2009).
31. Yamasaki, S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J. Hepatobiliary Pancreat Surg. 10, 288-291 (2003). (Pubitemid 37407518)
32. Slattery, J. M. & Sahani, D. V What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 11, 913-922 (2006). (Pubitemid 44373764)
33. Chung, Y E. et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 29, 683-700 (2009).
34. Nathan, H. & Pawlik, T. M. Staging of intrahepatic cholangiocarcinoma. Curr. Opin. Gastroenterol. 26, 269-273 (2010).
35. th edn (Springer, Chicago, 2009).
36. th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer doi:10.1002/cncr.25712.
37. Kokudo, N. & Arita, J. Staging for intrahepatic cholangiocarcinoma. Liver Int 30, 931-933 (2010).
38. Nathan, H. et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 16, 14-22 (2009).
39. Carpizo, D. R. & D'Angelica, M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg. Oncol. Clin. N. Am. 18, 289-305 (2009).
40. Giuliante, F. et al. Liver resection for intrahepatic cholangiocarcinoma. Tumori 91, 487-492 (2005). (Pubitemid 43251119)
41. Poultsides, G. A., Zhu, A. X., Choti, M. A. & Pawlik, T. M. Intrahepatic cholangiocarcinoma. Surg. Clin. North Am. 90, 817-837 (2010).
42. Yokoyama, Y et al. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br. J. Surg. 97, 1260-1268 (2010).
43. Murakami, Y et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann. Surg. Oncol. doi:10.1245/s10434-010-1325-4.
44. Burger, I. et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J. Vasc Interv. Radiol. 16, 353-361 (2005). (Pubitemid 40354852)
45. Ahmadzadehfar, H., Biersack, H. J. & Ezziddin, S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin. Nucl. Med. 40, 105-121 (2010).
46. Hong, K. & Geschwind, J. F. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin. Oncol. 37, 110-117 (2010).
47. Kiefer, M. V et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer doi:10.1002/cncr.25625.
48. Carrafiello, G. et al. Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience. Cardiovasc. Intervent Radiol. 33, 835-839 (2010).
49. Chiou, Y Y et al. Percutaneous ultrasound-guided radiofrequency ablation of intrahepatic cholangiocarcinoma. Kaohsiung J. Med. Sci. 21, 304-309 (2005).
50. Kim, J. H. et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur. J. Radiol. doi:10.1016/j.ejrad.2010.09.019.
51. Kopek, N., Holt, M. I., Hansen, A. T. & Hoyer, M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother. Oncol. 94, 47-52 (2010).
52. Czito, B. G., Anscher, M. S. & Willett, C G. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 20, 873-884 (2006). (Pubitemid 46940145)
53. Chen, Y X. et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 10, 492 (2010).
54. Tse, R. V et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Clin. Oncol. 26, 657-664 (2008). (Pubitemid 351264363)
55. Glimelius, B. et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. 7, 593-600 (1996). (Pubitemid 26285639)
56. Hezel, A. F. & Zhu, A. X. Systemic therapy for biliary tract cancers. Oncologist 13, 415-423 (2008). (Pubitemid 351679921)
57. Mazhar, D., Stebbing, J. & Bower, M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol. 2, 509-514 (2006). (Pubitemid 44304609)
58. Park, J. et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 3, 298-305 (2009).
59. Cho, S. Y et al. Survival analysis of intrahepatic cholangiocarcinoma after resection. Ann. Surg. Oncol. 17, 1823-1830 (2010).
60. Kassahun, W. T. & Jonas, S. Spectrum of benign lesions mimicking a malignant stricture at the iver hilum. Rev. Recent Clin. Trials 4, 185-194 (2009).
61. Sasaki, R. et al. Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma. Langenbecks Arch. Surg. 395, 615-623 (2010).
62. Bismuth, H. & Corlette, M. B. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg. Gynecol. Obstet. 140, 170-178 (1975).
63. Bismuth, H., Nakache, R. & Diamond, T. Management strategies in resection for hilar cholangiocarcinoma. Ann. Surg. 215, 31-38 (1992).
64. Jarnagin, W. R. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234, 507-517 (2001).
65. Blechacz, B. R., Sanchez, W. & Gores, G. J. A conceptual proposal for staging ductal cholangiocarcinoma. Curr. Opin. Gastroenterol. 25, 238-239 (2009).
66. Connor, S. et al. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J. Gastrointest. Surg. 9, 476-480 (2005). (Pubitemid 40431723)
67. El-Hanafy, E. Pre-operative biliary drainage in hilar cholangiocarcinoma, benefits and risks, single center experience. Hepatogastroenterology 57, 414-419 (2010).
68. Liu, F., Li, Y., Wei, Y. & Li, B. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig. Dis. Sci. doi:10.1007/s10620-010-1338-7.
69. Nagino, M. et al. Preoperative biliary drainage for biliary tract and ampullary carcinomas. J. Hepatobiliary Pancreat Surg. 15, 25-30 (2008). (Pubitemid 351279838)
70. Regimbeau, J. M. et al. Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC Study Group. J. Gastrointest Surg. doi:10.1007/s11605-011-1414-0.
71. Shimizu, H. et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann. Surg. 251, 281-286 (2010).
72. Lee, S. G. et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J. Hepatobiliary Pancreat Sci. 17, 476-589 (2010).
73. Neuhaus, P et al. Extended resections for hilar cholangiocarcinoma. Ann. Surg. 230, 808-818 (1999).
74. Jarnagin, W. R. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 234, 507-517 (2001).
75. Capussotti, L., Muratore, A., Polastri, R., Ferrero, A. & Massucco, P Liver resection for hilar cholangiocarcinoma: in-hospital mortality and longterm survival. J. Am. Coll. Surg. 195, 641-647 (2002). (Pubitemid 35285398)
76. Seyama, Y et al. Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann. Surg. 238, 73-83 (2003). (Pubitemid 38176410)
77. Kawasaki, S. et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann. Surg. 238, 84-92 (2003). (Pubitemid 38176411)
78. Hemming, A. W., Reed, A. I., Fujita, S., Foley, D. P & Howard, R. J. Surgical management of hilar cholangiocarcinoma. Ann. Surg. 241, 693-699 (2005).
79. Sano, T. et al. One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. Ann. Surg. 244, 240-247 (2006). (Pubitemid 44305538)
80. Shimizu, H. et al. Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann. Surg. 251, 281-286 (2010).
81. Nagino, M. et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann. Surg. 252, 115-123 (2010).
82. Anderson, C & Kim, R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 35, 322-327 (2009).
83. Sagawa, N., Kondo, S., Morikawa, T., Okushiba, S. & Katoh, H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg. Today 35, 548-552 (2005). (Pubitemid 40854019)
84. Vern-Gross, T. Z. et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J. Radiat Oncol. Biol. Phys. doi:10.1016/j.ijrobp.2010.05.001.
85. Schoenthaler, R. et al. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann. Surg. 219, 267-274 (1994).
86. Rea, D. J. et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann. Surg. 242, 451-458 (2005).
87. Soderlund, C & Linder, S. Covered metal versus plastic stents for malignant common bile duct stenosis: a prospective, randomized, controlled trial. Gastrointest Endosc 63, 986-995 (2006). (Pubitemid 43776145)
88. Brugge, W. R. Endoscopic techniques to diagnose and manage biliary tumors. J. Clin. Oncol. 23, 4561-4565 (2005). (Pubitemid 46196587)
89. Simmons, D. T. et al. A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma. Am. J. Gastroenterol. 101, 1792-1796 (2006). (Pubitemid 44166588)
90. Qian, X. J., Zhai, R. Y., Dai, D. K., Yu, P & Gao, L Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J. Gastroenterol. 12, 331-335 (2006). (Pubitemid 43336938)
91. Nag, S., DeHaan, M., Scruggs, G., Mayr, N. & Martin, E. W. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int. J. Radiat Oncol. Biol. Phys. 64, 736-744 (2006). (Pubitemid 43183568)
92. Shim, C S. et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 37, 425-433 (2005). (Pubitemid 40668207)
93. Matull, W. R. et al. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer. Liver Int 31, 99-107 (2011).
94. Witzigmann, H. et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann. Surg. 244, 230-239 (2006). (Pubitemid 44305537)
95. Zen, Y et al. Proposal of histological criteria for intraepithelial atypical/proliferative biliary epithelial lesions of the bile duct in hepatolithiasis with respect to cholangiocarcinoma: preliminary report based on interobserver agreement. Pathol. Int 55, 180-188 (2005). (Pubitemid 40676927)
96. Zen Y et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod. Pathol. 20, 701-709 (2007). (Pubitemid 46788877)
97. Wu, T. T., Levy, M., Correa, A. M., Rosen, C B. & Abraham, S. C Biliary intraepithelial neoplasia in patients without chronic biliary disease: analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic iver diseases. Cancer 115, 4564-4575 (2009).
98. Gatto, M. et al. Cholangiocarcinoma: update and future perspectives. Dig. Liver Dis. 42, 253-260 (2010).
99. Levy, C et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50, 1734-1740 (2005). (Pubitemid 41203674)
100. Iwatsuki, S. et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J. Am. Coll. Surg. 187, 358-64 (1988).
101. Rosen, C B., Heimbach, J. K. & Gores, G. J. Liver transplantation for cholangiocarcinoma. Transpl. Int 23, 692-697 (2010).
102. Sorensen, H. T. et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 28, 921-925 (1998). (Pubitemid 28450250)
103. Hakamada, K. et al. Late development of bile duct cancer after sphincteroplasty: a ten-to twenty-two-year follow-up study. Surgery 121, 488-492 (1997). (Pubitemid 27202893)
104. Su, C H., Shyr, Y M., Lui, W. Y & P'Eng, F. K. Hepatolithiasis associated with cholangiocarcinoma. Br. J. Surg. 84, 969-973 (1997).
105. Donato, F. et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 12, 959-964 (2001). (Pubitemid 34048878)
106. Lee, T. Y et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am. J. Gastroenterol. 103, 1716-1720 (2008).
107. Kobayashi, M. et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 88, 2471-2477 (2000). (Pubitemid 30331952)
108. Charlier, C et al. Cholangiocarcinoma in HIV-nfected patients with a history of cholangitis. J. Acquir. Immune. Defic. Syndr. 39, 253-255 (2005). (Pubitemid 40741127)
109. Lowenfels, A. B. & Norman, J. Isoniazid and bile duct cancer. JAMA 240, 434-435 (1978).
110. Yen, S., Hsieh, C C & MacMahon, B. Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history and oral-contraceptive use. Cancer 59, 2112-2116 (1987). (Pubitemid 17077800)
111. Rubel, L R. & Ishak, K. G. Thorotrast-associated cholangiocarcinoma: an epidemiologic and clinicopathologic study Cancer 50, 1408-1415 (1982). (Pubitemid 12031966)
112. Wong, O., Whorton, M. D., Foliart, D. E. & Ragland, D. An industry-wide epidemiologic study of vinyl chloride workers, 1942-1982. Am. J. Ind. Med. 20, 317-334 (1991).
113. Szendroi, M., Nemeth, L. & Vajta, G. Asbestos bodies in a bile duct cancer after occupational exposure. Environ. Res. 30, 270-280 (1983). (Pubitemid 13105256)
114. Lipsett, P A., Pitt, H. A., Colombani, P. M., Boitnott, J. K. & Cameron, J. L Choledochal cyst disease. A changing pattern of presentation. Ann. Surg. 220, 644-652 (1994). (Pubitemid 24355776)